Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. MicroPort Scientific Corporation
  6. News
  7. Summary
    853   KYG608371046

MICROPORT SCIENTIFIC CORPORATION

(853)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

MicroPort Scientific : ® Lifesciences Showcases Two Products at the 10th CSE Academic Conference on Diabetes and Gonadal Disorders

08/01/2021 | 04:32am EDT

Dalian, China, 30 July 2021 - Shanghai MicroPort Lifesciences Co. (MicroPort® Lifesciences) recently presented the La Fenice® Insulin Pump and the La Fenice® Hypophyseal Hormone Infusion Pump at the 10th Academic Conference on Diabetes and Gonadal Disorders. The conference, organized by the Gonad Research Group and the Diabetes Research Group of the Chinese Society of Endocrinology recently.

Bringing together more than 400 medical professionals, the event engaged with fundamental and clinical research, clinical treatment, clinical nutrition, prevention, care, drug development and other fields related to endocrine diabetes and gonadal disorders, to promote academic exchanges and collaboration among experts in these fields.

The La Fenice® Insulin Pump, which was showcased at the conference, is a medical aid developed by MicroPort® Lifesciences that uses artificial intelligence to manage insulin treatment. It provides a continuous subcutaneous infusion of insulin which aims to manage hyperglycemia at the normal secretion pattern of insulin, and provides insulin in pulses at five-minute intervals to mimic the basal rate of physiological insulin secretion. Using the La Fenice® Insulin Pump can promote a more effective control of blood sugar, and significantly reduces the risk of hypoglycemia by mitigating the differences in insulin absorption, thus improving patients' wellbeing.

The La Fenice® Hypophyseal Hormone Infusion Pump is the first-in-China GnRH pulse pump developed by MicroPort® Lifesciences. The pump works as an artificial hypothalamus simulating human gonadotropin-releasing hormone (GnRH) by providing continuous subcutaneous Gonarelin (LHRH) infusion via a microinfusion pump, which could stimulate excretion of luteinizing hormone (LH) and Follicle-Stimulating Hormone (FSH). The pump is used to treat Idiopathic hypogonadotropic hypogonadism (IHH), a type of hypogonadal hypoplasia caused by the deficiency of hypothalamic gonadotropin-releasing hormone (GnRH), which may be associated with loss or hyposmia of the sense of smell (also known as Kalman syndrome).

The La Fenice® Hypophyseal Hormone Infusion Pump could eventually help IHH patients to restore their fertility, and so far, hundreds of 'MicroPort® babies' have been born with the help of the La Fenice® Hypophyseal Hormone Infusion Pump, bringing hope to many IHH patients.

Prof. Xueyan Wu from the Department of Endocrinology of Peking Union Medical College Hospital notes, 'We used to adopt the androgen therapy for the treatment of patience with IHH, but the result was not favorable. Lately, we have switched to GnRH pulse therapy, which can mimic the normal pulse of the hypothalamic-pituitary-gonadal axis - and it works very well.'

Over recent years, the prevalence of infertility in China has climbed to 12.5%, with the overall incidence of IHH ranging from 1 to 10 per 100,000 of the population and a male-to-female ratio of 5:1.

Yimin Xu, Executive Director of MicroPort® Lifesciences, said, 'We will continue to work towards the company's vision of building a brand that belongs to patients. We remain committed to independent innovation and development to provide patients with a total solution to their physiological needs using microinfusion technology as a core platform.'

Disclaimer

MicroPort Scientific Corporation published this content on 01 August 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 01 August 2021 08:31:00 UTC.


© Publicnow 2021
All news about MICROPORT SCIENTIFIC CORPORATION
09/13MICROPORT SCIENTIFIC : Acquiring 45% Stake in Immunosuppressants Maker for $17 M..
MT
09/12MICROPORT SCIENTIFIC : ® Announces Strategic Investment with Kerui Pharma
PU
09/10MICROPORT SCIENTIFIC : ® NeuroTech NUMEN Coil Embolization System Approved for M..
PU
09/08MICROPORT SCIENTIFIC : Products Complete First Implantations in the UK Following..
PU
09/07MICROPORT SCIENTIFIC : ® Toumai® Laparoscopic Surgery Robot Becomes First in Chi..
PU
09/01MICROPORT SCIENTIFIC : First Motorized Retrievable Transcatheter Aortic Valve (T..
PU
08/31MICROPORT SCIENTIFIC : Loss Rises on Higher R&D Spending, Price Reduction
MT
08/29MICROPORT SCIENTIFIC : ® EP OptimAblate™ Tubing Set Receives NMPA Marketin..
PU
08/24MICROPORT SCIENTIFIC : MSC Completes First Patient Enrollment for Multicenter Po..
PU
08/12MICROPORT SCIENTIFIC : CardioFlow Medtech's Next-generation Alwide® Plus Balloon..
PU
More news
Financials (USD)
Sales 2021 784 M - -
Net income 2021 -141 M - -
Net cash 2021 1 079 M - -
P/E ratio 2021 -82,0x
Yield 2021 0,07%
Capitalization 11 167 M 11 167 M -
EV / Sales 2021 12,9x
EV / Sales 2022 10,4x
Nbr of Employees 8 303
Free-Float 45,2%
Chart MICROPORT SCIENTIFIC CORPORATION
Duration : Period :
MicroPort Scientific Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MICROPORT SCIENTIFIC CORPORATION
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 9
Last Close Price 6,23 $
Average target price 7,43 $
Spread / Average Target 19,4%
EPS Revisions
Managers and Directors
Zhao Hua Chang Chairman & Chief Executive Officer
Hong Bin Sun Chief Financial Officer
Qi Yi Luo Chief Technology Officer
Glendy Wang Chief Operating Officer
Jonathan H. Chou Independent Non-Executive Director
Sector and Competitors